close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

InMed Pharmaceuticals Inc. - Common Shares (NQ:INM)

0.9403 -0.0413 (-4.21%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about InMed Pharmaceuticals Inc. - Common Shares

< Previous 1 2 3 4 5 6 7 Next >
CBDNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Poised to Become Global Leader in Manufacture of Rare Cannabinoids
Via Investor Brand Network
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Begins Phase 2 Clinical Trial Evaluating CBN in the EB Treatment
Via CannabisNewsWire
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Begins Phase 2 Clinical Trial Evaluating CBN in the EB Treatment
Via Investor Brand Network
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Eyes Commercial Plans to Become B2B Wholesale Supplier of Rare Cannabinoids
Via Investor Brand Network
Topics Supply Chain
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Eyes Commercial Plans to Become B2B Wholesale Supplier of Rare Cannabinoids
Via CannabisNewsWire
Topics Supply Chain
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Release FY 2021 Financial Report and Corporate Update
Via Investor Brand Network
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Release FY 2021 Financial Report and Corporate Update
Via CannabisNewsWire
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) to Release FY 2021 Financial Report, Acquire BayMedia
Via CannabisNewsWire
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) to Release FY 2021 Financial Report, Acquire BayMedia
Via Investor Brand Network
News headline image
InMed Pharmaceuticals (INM): Acquiring BayMedica
LONDON, UK / ACCESSWIRE / September 20, 2021 / InMed has announced that it has entered into a definitive agreement to acquire BayMedica, a private US-based company that is focusing on the manufacture... 
From Edison Investment Research Limited
Via AccessWire
InMed Pharmaceuticals Inc. (NASDAQ: INM) Signs Definitive Agreement to Acquire 100% of BayMedica Inc., Positioning it to Stand Distinct in Rare Cannabinoids Manufacturing, Become a Revenue-Generating Company, Expand Drug Development Capabilities
Via CannabisNewsWire
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Enters Definitive Agreement for ‘Transformative’ Acquisition of Leading Manufacturer of Rare Cannabinoids
Via CannabisNewsWire
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) to Present at H.C. Wainwright 23rd Annual Global Investment Conference
Via CannabisNewsWire
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Slated for Live Webcast at VirtualInvestorConferences.com
Via CannabisNewsWire
InMed Pharmaceuticals Inc. (NASDAQ: INM) Presents CBN-Based Treatment for Glaucoma at H.C. Wainwright Ophthalmology Virtual Conference
Via CannabisNewsWire
Topics Cannabis
InMed Pharmaceuticals Inc. (NASDAQ: INM) Pursues Commercial Production of Rare Cannabinoids at Pharmaceutical Levels
Via CannabisNewsWire
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) to Present at H.C. Wainwright Ophthalmology Virtual Conference
Via CannabisNewsWire
InMed Pharmaceuticals Inc. (NASDAQ: INM) and Its Quest to Build an Industry-Leading, Rare Cannabinoid Enterprise
Via CannabisNewsWire
420 with CNW — Patients with High-Grade Gliomas Register Improved Quality of Life after Using Medical Marijuana
Via CannabisNewsWire
Topics Cannabis
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Continues Optimization of IntegraSyn(TM) to Increase Cannabinoid Yield
Via CannabisNewsWire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today